Completed
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
NCT00939627
- Conditions
- Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, +49 more
- Locations
-
- H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States
- Emory University/Winship Cancer Institute Atlanta, Georgia, United States
- Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States
- Suburban Hospital Bethesda, Maryland, United States